Company intelligence / Profile preview

Chengdu Sagaer Pharmaceutical

Chengdu, Sichuan, Chinasciencedirect.com ↗

Ownership: Private
Development stage: Other

Overview

Chengdu Sagaer Pharmaceutical is a Chinese pharmaceutical company engaged in the development and clinical testing of small molecule drugs and traditional Chinese medicine formulations. The company has advanced at least two products into late-stage clinical trials—Tangjiang Shenkang Granules for diabetic nephropathy reached phase 3 studies, while Dinggui oil Soft Capsule is also reported at phase 3 for irritable bowel syndrome with diarrhea. Clinical results include randomized controlled multicenter studies demonstrating efficacy and safety endpoints.

Therapeutic areas: NephrologyGastroenterology
Modalities: Small moleculeTraditional Chinese medicine-derived products
Industry: Biotech

Beyond the preview

Go deeper on Chengdu Sagaer Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu Sagaer Pharmaceutical.

Explore the full profile